---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145682"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-15T00:08:42.418330+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks closes transfer of zanidatamab program to Jazz; amends collaboration agreement

## Summary
- Jazz acquired 100% of Zymeworks subsidiary ZZI and certain assets; Zymeworks transferred employees and contracts for zanidatamab program.
- Under amended agreement, Jazz is solely responsible for development, regulatory, and commercial activities; costs borne directly by Jazz.
- Zymeworks will continue to supply zanidatamab for clinical sites performing the program.
- Original financial terms unchanged; some costs expected to be unrecoverable, to be finalized by mid-2023.
- Jazz's nonexclusive license expanded to research and develop Licensed Products outside the Territory for the Program.

## SEC filing metadata
- accession: 0001193125-23-145682
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312523145682/0001193125-23-145682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312523145682/d481028d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145682
- JSON: https://secwatch.observer/filing/0001193125-23-145682.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145682.txt

## Key facts
- Material Agreements
  Zymeworks Inc. amended Amended and Restated License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited valued at Amendment to transfer responsibility for the Program to Jazz, with unchanged financial terms except (effective 2023-05-15).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Jazz Pharmaceuticals Ireland Limited
  - Value: Amendment to transfer responsibility for the Program to Jazz, with unchanged financial terms except
  - Effective: 2023-05-15
  source text: Amended Jazz Collaboration Agreement As previously disclosed, on October 18, 2022, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), entered into a License and Collaboration Agreement (the “Original Jazz Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as “Jazz”), an affiliate of Jazz Pharmaceuticals, Inc. (“Jazz Inc.”), granting Jazz exclusive rights to develop and commercialize Zymeworks BC’s proprietary bispecific HER2 antibody product candidate known as zanidatamab throughout the world, but excluding existing Asia Pacific territories (other than Japan) already governed by Zymeworks BC’s agreement with BeiGene, Ltd. (the “Territory”). As previously disclosed, as part of the Transactions contemplated by the Transfer Agreement (as these terms are defined below), on May 15, 2023, Zymeworks BC and Jazz entered into an Amended and Restated License and Collaboration Agr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312523145682/0001193125-23-145682-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.